Supply Chain Intelligence

Vir Biotechnology, Inc. Supply Chain

VIR supply chain intelligence for Vir Biotechnology, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

VIR ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

7Suppliers
7Customers
3Debt Items
20Related Chains

Vir Biotechnology, Inc. Suppliers

TickerNameConfidenceEvidence
INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE INSTITUTE-FOR-RESEARCH-IN-BIOMEDICINE 92% Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs
SANOFI-S-A SANOFI-S-A 90% Under the terms of Vir Bio's licensing agreement with Sanofi, Vir Bio will share a portion of certain collaboration proceeds received from Astellas with Sanofi
THE-ROCKEFELLER-UNIVERSITY THE-ROCKEFELLER-UNIVERSITY 90% Pursuant to the Rockefeller Agreement, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller
SNY Sanofi 72% Reciprocal relationship from SNY graph: . The license agreement entered into with Vir Biotechnology, Inc. in September 2024 led to the derecognition of the ProXTen intangible asset. For further infor…
SNYNF Sanofi 72% candidates, the competitive position of our product candidates, and import or export of raw materials and product used in our drug development, clinical manufacturing and future commercial activities…
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: candidates, the competitive position of our product candidates, and import or export of raw materials and product use…
XNCR Xencor, Inc. 72% Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR gra…

Vir Biotechnology, Inc. Customers

TickerNameConfidenceEvidence
USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES 95% USAspending awards from Department of Health and Human Services: $65,867,804 across 1 awards. 75A50122C00081 VIR BIOTECHNOLOGY - OTA FOR PRE-EXPOSURE PROPHYLACTIC MONOCLONAL ANTIBODIES FOR THE PREVEN…
ASTELLAS-US-LLC ASTELLAS-US-LLC 92% Vir Bio has agreed to grant to Astellas, subject to certain intellectual property rights of Sanofi S.A. (Sanofi), an exclusive license to develop, manufacture, commercialize and otherwise exploit VIR-5500
NORGINE NORGINE 92% The Company determined that Norgine is a customer with respect to the delivery of Norgine License
GATES-FOUNDATION GATES-FOUNDATION 90% The Company accounted for the common stock issued to the Gates Foundation based on its fair market value on the closing date
SNYNF Sanofi 72% Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VIR graph: e of Contents VIR BIOTECHNOLOGY, IN…
SNYNF Sanofi 72% e of Contents VIR BIOTECHNOLOGY, INC. Notes to Consolidated Financial Statements $ $ Less: Segment expenses (1) Cost of revenue Research and development Personnel (2) Licenses, collaborations and con…
ENCENTRIO-THERAPEUTICS-INC ENCENTRIO-THERAPEUTICS-INC 62% n our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. In addition, under our l…

Vir Biotechnology, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VIR-DEBT-13360 Xbrl Convertible 90% xbrl convertible detail from xbrl 2019-12-31.
VIR-DEBT-13359 Warrants outstanding: 2049000 90% xbrl warrant detail from xbrl 2019-12-31.
VIR-DEBT Debt stack $95.6M 90% Market cache reports total debt of $95.6M.

Vir Biotechnology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Vir Biotechnology, Inc..

Vir Biotechnology, Inc. Ownership

HolderNameConfidenceEvidence
VIR-OWNER-BLACKROCK-INC BlackRock, Inc. 90% 13F overlay lists BlackRock, Inc. as top holder; 257 tracked holders.

Vir Biotechnology, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ATOS Atossa Therapeutics, Inc. 100.00 2
CALC CalciMedica, Inc. 100.00 2
EDIT Editas Medicine, Inc. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
ANRO Alto Neuroscience, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BLRX BioLineRx Ltd. 100.00 2
CYTK Cytokinetics, Incorporated 100.00 2
CBIO Crescent Biopharma, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
ALXO ALX Oncology Holdings Inc. 100.00 2
CCEP Coca-Cola Europacific Partners PLC 100.00 2
DSGN Design Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
BIOA BioAge Labs, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
DBVTF DBV TECHNOLOGIES 100.00 2
NVO Novo Nordisk A/S 100.00 2
View VIR supply chain intel →

Explore the full interactive supply chain map for Vir Biotechnology, Inc..

Open VIR supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map